Bispecifics and multispecifics at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
40 organizations at Antibody Engineering 2026 present work in bispecifics & multispecifics: 22 drug developers, 10 suppliers and service providers and 8 academic, government and non-profit bodies. Between them they bring 68 presentations to the program. Most represented: Xencor (4 on the program), AstraZeneca (3 on the program), Amgen (3 on the program). As of Nov 10, 2026.
Format
Top represented
Showing 1–10 of 40 organizations
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
Xencor Pasadena, CA | |
Develops engineered antibodies using its XmAb Fc and bispecific technologies, for cancer and autoimmune diseases. | Chair Sun Dec 13 1:00pm–1:15pm Talk Sun Dec 13 4:15pm–5:00pm Chair Mon Dec 14 8:00am–8:05am Talk Mon Dec 14 10:55am–11:30am Chair Wed Dec 16 8:10am–8:15am Talk Wed Dec 16 9:15am–9:45am XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life Redesigned antibody arms that pair only with their intended partner, used to build two-target antibodies that last longer in blood. Bispecifics & multispecifics |
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing antibodies, antibody-drug conjugates and multispecifics in oncology and other diseases. | Talk Sun Dec 13 11:00am–11:45am Keynote Mon Dec 14 10:20am–10:55am From Insight to Impact: Translational Medicine as a Driver of ADC Clinical Success and Future Innovation Why finding biological markers of response early helps antibodies carrying a cell-killing drug succeed in patients. ADCs & conjugates Talk Wed Dec 16 10:30am–11:00am CD8-Guided T Cell Engager with Potent Preclinical Efficacy and Superior Therapeutic Index An antibody that pulls killer T cells onto liver cancer cells while rousing fewer of the T cells that drive dangerous immune reactions. Chair Wed Dec 16 2:10pm–2:15pm Talk Wed Dec 16 2:15pm–2:45pm |
Amgen Thousand Oaks, CA | |
Global biopharmaceutical company developing and manufacturing biologic medicines, including bispecific T-cell engagers. | Chair Sun Dec 13 1:00pm–1:15pm Talk Sun Dec 13 1:15pm–1:45pm Developability-Guided Generative Biology for Therapeutic Protein Engineering Designing new therapeutic proteins by computer while checking from the start that they can be made and purified. AI & computational design Talk Sun Dec 13 4:15pm–5:00pm Talk Mon Dec 14 5:45pm–6:15pm Induced Proximity and Next-Generation Antibody Therapeutics Bispecifics & multispecifics |
Genentech South San Francisco, CA | |
Biotechnology company and Roche Group member that discovers, develops and markets antibody and other medicines. | Talk Sun Dec 13 11:00am–11:45am Talk Mon Dec 14 2:30pm–3:00pm Dissecting the Mechanisms of Action of PROTABs: Insights into Designing Antibody-Based Protein Degraders How the shape of antibody binding decides whether a target protein on the cell surface is actually destroyed. Bispecifics & multispecifics Chair Tue Dec 15 8:10am–8:15am Talk Tue Dec 15 8:15am–8:45am From COVID to Cancer: LNP-mRNA as an Antigen Format for Antibody Discovery Against Challenging Membrane Proteins Immunizing animals with mRNA packaged in tiny fat particles, so their antibodies recognize proteins embedded in cell membranes. Protein engineering |
Regeneron Tarrytown, NY | |
Biotechnology company that discovers, develops and markets antibody medicines, including bispecific antibodies, using its VelocImmune mouse platform. | Talk Sun Dec 13 3:45pm–4:15pm From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics How measurements of drug levels and effects in the body guide the first human dose and the final approved dosing schedule. Talk Mon Dec 14 5:15pm–5:45pm Targeting IgE Responses Beyond oncology Chair Wed Dec 16 8:10am–8:15am |
University of Southampton Southampton, United Kingdom | |
Public research university whose Centre for Cancer Immunology works on antibody immunotherapy and Fc receptor biology. | Chair Mon Dec 14 2:25pm–2:30pm Talk Mon Dec 14 4:45pm–5:15pm Disulfide Engineering of Immunostimulatory Antibodies for Augmented Receptor Agonism and Immune Cell Stimulation Adding chemical bridges between an antibody's two arms to lock its shape and make it switch on immune cells more strongly. Protein engineering Chair Tue Dec 15 8:10am–8:15am |
RT Rondo Therapeutics Hayward, CA | |
Develops bispecific T cell engagers, including co-stimulatory CD28 bispecifics, for solid tumors. | Chair Sun Dec 13 9:00am–9:10am Session Co-Chair Welcome and Opening Remarks Short research talks by scientists within ten years of their graduate degree, plus career advice and time to meet peers. Chair Tue Dec 15 2:25pm–2:30pm Talk Tue Dec 15 2:30pm–3:00pm Combination of Signal 1 and Signal 2 T Cell Engagers for Treatment of Ovarian Cancer Pairing two antibodies that give T cells both of the signals they need, aiming at ovarian cancer that no longer responds to platinum drugs. Chair Wed Dec 16 8:10am–8:15am |
Twist Bioscience South San Francisco, CA | |
Synthetic DNA company whose biopharma unit provides antibody libraries and antibody discovery and optimization services. | Booth Exhibiting at Booth 200 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 12:15pm–1:15pm Scaling Wet-Lab Validation for AI-based Biologic Discovery Why lab testing has become the bottleneck for AI antibody design, and how a shared model platform from Eli Lilly connects to it. AI & computational designAntibody discovery Talk Tue Dec 15 1:40pm–2:00pm Screening in the Format You’ll Develop In: Cell-Free Expression of Full-Length IgG Making full-length antibodies without cells at screening scale, and how their binding compares with the same antibodies made in mammalian cells. Antibody discovery Talk Wed Dec 16 7:30am–8:00am Engineering for Better Bispecifics: Introducing the B-Body® Platform A two-target antibody design meant to assemble reliably, avoiding low yields and hard purification when production scales up. Bispecifics & multispecificsDevelopability & CMC |
Fully human antibody discovery built on its Harbour Mice transgenic platforms for conventional and heavy-chain-only antibodies, offered as integrated discovery services. | Booth Exhibiting at Booth 203 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 1:45pm–2:15pm A Fully Human, AI-native Discovery and Development Platform for Next-generation Modality Solutions How fully human antibody mice combined with AI design feed immune cell engagers, brain-crossing antibodies, drug conjugates and other complex formats. Antibody discoveryAI & computational design Talk Tue Dec 15 11:30am–12:00pm VHH to Mice – With a Focus on In vivo Discovery/Screening Approaches for Therapeutic Discovery Applications Why single-domain human antibodies from engineered mice suit CAR-T cells and T-cell engagers, and how testing for target-cell killing picks better candidates. Bispecifics & multispecifics |
City of Hope Duarte, CA | |
Cancer research and treatment center with a graduate school. | Talk Wed Dec 16 4:15pm–4:45pm MPACT: Engineering the Fc–FcγR Interface for Plug-and-Play, Mixed-Valency Multispecific Antibodies Using a chemical bond at a natural antibody contact point to snap extra targeting or immune-activating parts onto one antibody. Bispecifics & multispecifics Talk Wed Dec 16 4:15pm–4:45pm Turning up the Heat: Radioimmunoconjugates for Targeted Radiation Therapy Using antibodies and smaller antibody pieces to carry radioactive atoms that both image and irradiate tumors. |
Find buyers in bispecifics & multispecifics
Tell us what you sell and we’ll find the people at organizations working on bispecifics & multispecifics most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse Antibody Engineering 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction